(Abstracted from Lancet 2019;394:497–509)
To date, a total of 99 countries and territories have introduced population-level human papillomavirus (HPV) vaccination programs. Early adopting countries have served as models and produced observational and epidemiological data on the ability of such programs in preventing HPV-related infections and diseases.
Centre de recherche du CHU de Québec (M.D., E.B., N.P., M.B.) and Département de médecine sociale et préventive, Faculté de médecine, Université Laval (E.B., M.B.), Québec, QC, Canada; and Department of Infectious Disease Epidemiology, Imperial College, London, United Kingdom (M.B.)